# | Title | Journal | Year | Citations |
---|
1 | Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma | New England Journal of Medicine | 2009 | 7,606 |
2 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Lancet, The | 2010 | 5,899 |
3 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Lancet, The | 2018 | 3,542 |
4 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Lancet, The | 2017 | 3,224 |
5 | Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer | New England Journal of Medicine | 2013 | 3,181 |
6 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer | New England Journal of Medicine | 2014 | 2,808 |
7 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 2,771 |
8 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1,816 |
9 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
10 | JENDL-4.0: A New Library for Nuclear Science and Engineering | Journal of Nuclear Science and Technology | 2011 | 1,716 |
11 | Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Hepatology International | 2017 | 1,537 |
12 | International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study | Lancet, The | 2018 | 1,487 |
13 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | Lancet Oncology, The | 2020 | 1,363 |
14 | All-solid-state Z-scheme in CdS–Au–TiO2 three-component nanojunction system | Nature Materials | 2006 | 1,266 |
15 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial | Journal of Clinical Oncology | 2020 | 1,255 |
16 | Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma | New England Journal of Medicine | 2018 | 1,253 |
17 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 1,202 |
18 | Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma | JAMA Oncology | 2016 | 1,192 |
19 | High performance plasma amyloid-β biomarkers for Alzheimer’s disease | Nature | 2018 | 1,180 |
20 | Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours | Journal of Pathology | 2014 | 1,151 |
21 | High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast Material | Radiology | 2014 | 1,112 |
22 | Role of oxygen vacancy in the plasma-treated TiO2 photocatalyst with visible light activity for NO removal | Journal of Molecular Catalysis A | 2000 | 1,110 |
23 | The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) | Hypertension Research | 2019 | 1,047 |
24 | Regulation and function of ascorbate peroxidase isoenzymes | Journal of Experimental Botany | 2002 | 1,021 |
25 | CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth | Cancer Cell | 2011 | 1,020 |
26 | Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia | Nature | 2011 | 1,016 |
27 | Insights into Land Plant Evolution Garnered from the Marchantia polymorpha Genome | Cell | 2017 | 973 |
28 | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma | Hepatology International | 2010 | 944 |
29 | Eight Calves Cloned from Somatic Cells of a Single Adult | Hepatology International | 1998 | 932 |
30 | Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer | Journal of Clinical Oncology | 2015 | 924 |
31 | The Chemokine Superfamily Revisited | Immunity | 2012 | 914 |
32 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer | New England Journal of Medicine | 2019 | 904 |
33 | Galactinol and Raffinose Constitute a Novel Function to Protect Plants from Oxidative Damage | Plant Physiology | 2008 | 888 |
34 | Aspects of Grand Unified Models with Softly Broken Supersymmetry | Progress of Theoretical Physics | 1982 | 767 |
35 | Neonicotinoids: insecticides acting on insect nicotinic acetylcholine receptors | Trends in Pharmacological Sciences | 2001 | 760 |
36 | Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial | Lancet, The | 2017 | 753 |
37 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
38 | Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer | JAMA Oncology | 2018 | 735 |
39 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma | Journal of Clinical Oncology | 2020 | 723 |
40 | Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial | Lancet, The | 2009 | 685 |
41 | Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial | Journal of Clinical Oncology | 2013 | 678 |
42 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Lancet Oncology, The | 2014 | 678 |
43 | Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial | Journal of Clinical Oncology | 2012 | 676 |
44 | Cancer classification using the Immunoscore: a worldwide task force | Journal of Translational Medicine | 2012 | 676 |
45 | Visible-light-active titanium oxide photocatalyst realized by an oxygen-deficient structure and by nitrogen doping | Applied Catalysis B: Environmental | 2003 | 668 |
46 | Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment | Proceedings of the National Academy of Sciences of the United States of America | 2013 | 658 |
47 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC | Nature | 2021 | 649 |
48 | Design concepts for the Cherenkov Telescope Array CTA: an advanced facility for ground-based high-energy gamma-ray astronomy | Experimental Astronomy | 2011 | 640 |
49 | Clinical features of isolated noncompaction of the ventricular myocardium | Journal of the American College of Cardiology | 1999 | 636 |
50 | Mordred: a molecular descriptor calculator | Journal of Cheminformatics | 2018 | 622 |